Summary. Binding of 1251-heparan sulphate was a common property of Helicobacter pylori strains isolated from patients with gastroduodenal ulcer diseases. Binding was (i) saturable ; (ii) reversible by the addition of unlabelled heparan sulphate and heparin; (iii) inhibited by unlabelled heparan sulphate, heparin, and heparin oligosaccharides but not by other glycosaminoglycans of comparable size (chondroitin sulphate and dermatan sulphate) or by highly glycosylated glycoproteins (hog gastric mucin and fetuin) ; (iv) reduced by heat treatment (SOOC, 10 min) and exposure of the bacteria to pronase E, proteinase K, trypsin and chymotrypsin, but unaffected by treatment with pepsin and neuraminidase ; and (v) time-, pH-, and ionic strength-dependent. Scatchard plot analysis of the binding data indicated the presence of one class of high-affinity receptor (K, = 9 x lo-' M) for heparan sulphate.
Introduction
Helicobacter pylori, previously called Carnpylobacter pytori,' is a highly motile organism which penetrates the gastric mucin layer and colonises the gastric epithelium or ectopic gastric tissues in other parts of the intestinal tract, such as gastric metaplasia in the d u~d e n u m .~~~ It has been reported4-' recently to express sialic acid-specific agglutinating activity against erythrocytes of various animal species. The aim of this study was to examine the interaction between H . pylori and the acidic glycosaminoglycan heparan sulphate, a component of cell-surface or basement membrane-associated proteoglycans produced by both epithelial and mesenchymal cells.' Our working hypothesis was that H. pylori could use heparan sulphate-specific adhesin(s), in addition to the previously reported sialic acid-specific haemagglutinin(s) or ad he sin(^),^-^ to colonise gastric tissues.
Materials and methods

Strains and culture conditions
The 17 strains of H pylori examined were from our laboratory collection.** 7 7 Generally, bacterial strains were grown under micro-aerophilic conditions at 37" for 3-5 days on Blood Agar Base No. 1 (Lab M) with defibrinated horse blood 5% v/v. The bacteria were harvested with 0.01 M potassium phosphate buffer, pH 7.2, containing 0.15 M NaCl (1 ml/plate), washed Received I : Correspondence should be sent to Professor T. Wadstrom. once and suspended in 0.1 M sodium acetate buffer, pH 4, containing 0.15 M NaCl (acetate buffer), to a final density of 10" cfu/ml.
Chemicals
Highly purified preparations of glycosaminoglycans (hyaluronan, bovine lung heparan sulphate, bovine cartilage chondroitin sulphate, porcine skin dermatan sulphate, and porcine intestinal heparin were obtained as described previously.l09 Heparin oligosaccharides, isolated after partial de-aminative cleavage of heparin with nitrous acid and fractionated by gel chromatography, essentially as described previously,12 were kindiy provided by Dr U. Lindahl (Department of Veterinary Medical Chemistry, Swedish University of Agricultural Sciences, Uppsala, Sweden). Dextran (M, 500000) was obtained from Pharmacia and dextran sulphates (M, 5000 and 500000) were from Sigma. All other chemicals were of analytical grade and were purchased from various commercial sources.
Binding assay
Heparan sulphate was derivatised at the aminoterminal serine residue with p-hydroxyphenyl propionate and radio-iodinated." The binding of 1251-heparan sulphate by H. pylori was quantified as described previo~s1y.l~ Briefly, samples of an 1251-labelled heparan sulphate solution (50 pl containing c. 20 1251-heparan sulphate binding-inhibition assay H. pylori suspensions (100 pl containing lo9 cells) were incubated at 20°C for 1 h with 100 pg (50 pg/ml final concentration) of unlabelled heparan sulphate, chondroitin sulphate, dermatan sulphate, heparin, hyaluronan, heparin oligosaccharides, fetuin, hog gastric mucin, dextran sulphate (high and low mol. wt), and dextran. The treated cells were washed with 2 ml of PBS, suspended in 100 pl of either PBS or acetate buffer, and used in the binding assay described above.
Enzymatic digestion of bacterial cells
H , pylori suspensions (100 pl containing lo9 cells) were treated with 1OOpg (50pg/ml final concentration) of pepsin (in 0.1 M sodium acetate buffer, pH 5 . Q Streptornyces griseus-pronase E, Tritirachiurn album-proteinase K, trypsin, and chymotrypsin (in 50 mM Tris-HC1 buffer, pH 7, containing 5 mM CaCl,), or Vibrio cholerae-neuraminidase (in PBS) at 37°C for 1 h, as described in the Worthington Enzyme Manual.14 Cells were washed twice with PBS (4 ml), suspended in acetate buffer (pH 4) at the original cell concentration, and used in the binding assays described above.
Results
Preliminary screening of 17 H. pylori strains for binding of 1251-labelled heparan sulphate showed that 90% of the strains studied bound this glycosaminoglycan. H . pylori strains 25 and 1139, which showed moderate binding and which have previously been examined for haemagglutinins,', were selected for further characterisation of heparan sulphatebinding.
Increasing amounts of heparan sulphate were incubated with strain 25 (fig. l) , and saturation of the binding sites was obtained within the concentration range used. Scatchard plot analysis of the binding data gave a straight line ( fig. 1, inset) , which indicated the presence of one class of heparan sulphate receptor. The dissociation constant (K,) of 9 x lo-' M, calculated from the slope of the line, indicated that heparan sulphate bound to H. pylori with a high affinity. Binding was time-dependent ( fig. 2) , and reversible by unlabelled heparan sulphate ( fig. 3) . Cellbound lZ5I-heparan sulphate was displaced by an excess of both unlabelled heparan sulphate ( fig. 4a ) and the analogous glycosaminoglycan heparin ( fig.  4b) . Binding was pH-and ionic strength-dependent (table I); binding was optimal at pH 4 and was inhibited in high ionic-strength solutions, e.g., 2 M NaCl virtually abolished binding. Divalent cations (Ca++, Mg++, Mn++, Fe++) and EDTA (all at 1 mM final concentration) did not affect heparan sulphate binding by the bacteria (data not shown). Pre-treatment of H. pylori with unlabelled heparan sulphate and heparin inhibited binding of '251-heparan sulphate (table 11) . However, other glycosaminoglycans of similar size (chondroitin sulphate and dermatan sulphate), highly glycosylated glycoproteins (hog gastric mucin and fetuin), and various carbohydrates (fucose, mannose, galactose, glucosamine and N-acetybglucosamine) did not inhibit binding. High and low-mol. wt dextran sulphates (but not highmol. wt dextran) were also found to inhibit heparan sulphate-binding (table 11) . Heparin oligosaccharides were also tested for their ability to inhibit heparan sulphate-binding (fig. 5) . The degree of inhibition increased gradually with increasing chain length. Heparin oligosaccharides longer than 10 saccharide residues gave 2 50% inhibition. Heat-treatment (SOOC, 10 min) of the bacteria reduced their heparan sulphate-binding activity by c. 90% (table 111) . Binding was unaffected after treatment of the bacteria with pepsin and neuraminidase, but was reduced by 50-70 YO by exposure to pronase E, proteinase K, trypsin and chymotrypsin (table 111) . Results of heat-and enzyme-inactivation studies suggested that the heparan sulphate-binding componen t (s) was pro teinaceous.
Strain 25
Strain 1139 H. pylori strains were screened for binding to the extracellular matrix component heparan sulphate. Of the H . pylori strains studied, 90%, regardless of haemagglutination pat terns, bound 251-heparan sulphate. Strains 25 and 1139, which have previously been studied with regard to other cell-surface proper tie^,^? ' were selected for further characterisation.
Binding of lZ5I-heparan sulphate by H. pylori was consistent with the concept that the interaction involves protein receptor-ligand binding. Binding was (i) saturable, (ii) of high affinity and reversible by unlabelled heparan sulphate or heparin added in excess, (iii) inhibited by unlabelled heparan sulphate, heparin and heparin oligosaccharides but not by other glycosaminoglycans or glycoproteins, and (iv) sensitive to proteinase and heat treatments. The low binding at high pH (pH 8) and the high binding at low pH (pH 4), as well as the inhibition of binding at high ionicstrength (2 M NaCl) suggest that charge interactions are important for optimal binding. However, the specificity of the interaction appears to be similar to that of heparan sulphate-binding by herpes simplex virus,12 in which heparin oligosaccharides inhibit heparan sulphate-binding. The proteinaceous bindingsite on H . pylori appears to have a strong positive charge at pH4, as heparan sulphate has a negative charge at pH 4.5 Interestingly, other negativelycharged glycosaminoglycans, such as dermatan sulphate and chondroitin sulphate, did not inhibit binding (table 11) , thus suggesting that binding also has some specificity for polysaccharides with a particular chain geometry and distribution of negative charges. On the other hand, in view of the fact that we used bovine lung heparan sulphate and porcine intestinal heparin in our studies, further studies need to be performed to characterise the interactions between H.
pylori and heparan sulphate derived from human gastric tissues.
The observation that pepsin-treated H. pylori retained the ability to bind '251-heparan sulphate, and that binding had a low pH optimum (pH 4), may be significant in the pathogenesis of the gastric infection caused by this microbe. Thus, the presence of pepsin and the acidic pH of the gastric environment associated with H. pylori colonisation may not affect the attachment of bacteria to heparan sulphate. In any case, the ability of H. pylori to adhere to and penetrate the gastric mucosa could requirea variety of additional bacterial surface proteins, toxins and enzymes. Further studies need to be done to determine whether antibodies to heparan sulphate-binding protein(s) are present in the various stages of the gastric disease process, and whether patients' sera block heparan sulphate binding by H. pylori. Studies on the isolation, purification and characterisation of the H . pylori-
